Sasanka M. Handunnetti

Brisbane, QLD, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment.

Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment.

Journal: Blood neoplasia
Published: February 13, 2026

Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.

Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.

Journal: Leukemia & lymphoma
Published: July 27, 2025

Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.

Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.

Journal: Blood advances
Published: April 08, 2025

Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.

Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.

Journal: Blood advances
Published: April 08, 2025

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.

Journal: Blood
Published: November 22, 2023

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.

Journal: Blood advances
Published: July 28, 2023

Development of a distributed international patient data registry for hairy cell leukemia.

Development of a distributed international patient data registry for hairy cell leukemia.

Journal: Leukemia & lymphoma
Published: September 07, 2022

Treatment approaches for patients with TP53-mutated mantle cell lymphoma.

Treatment approaches for patients with TP53-mutated mantle cell lymphoma.

Journal: The Lancet. Haematology
Published: September 04, 2022

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.

Journal: Blood advances
Published: June 13, 2022

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.

Journal: Internal medicine journal
Published: April 13, 2022

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.

Journal: Blood advances
Published: September 28, 2021

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.

Journal: Blood
Published: June 01, 2021
Showing 1-12 of 25

Last Updated: 09/26/2026